Randomized controlled multicenter trial on the effectiveness of the collagen hemostat Sangustop® compared with a carrier-bound fibrin sealant during liver resection (ESSCALIVER study, NCT00918619)

Langenbeck's Archives of Surgery

Volumn 399, Issue 6, 2014, Pages 725-733

  Moench, C ^a   Mihaljevic, A L ^b   Hermanutz, V ^c   Thasler, W E ^d   Suna, K ^e   Diener, M K ^f   Seehofer, D ^g   Mischinger, H J ^h   Jansen Winkeln, B ⁱ   Knaebel, H P ^c   Bechstein, W O ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c B Braun Melsungen AG   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e KRANKENHAUS NORDWEST   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h MEDICAL UNIVERSITY OF GRAZ   (Austria)

ⁱ JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Carrier bound fibrin sealant; Collagen hemostat; Hemostatics; Liver resection; Randomized controlled trial

Indexed keywords

FIBRIN GLUE; FIBRINOGEN PLUS THROMBIN; MICROCRYSTALLINE COLLAGEN; COLLAGEN; HEMOSTATIC AGENT;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEVICE SAFETY; ELECTIVE SURGERY; FEMALE; FOLLOW UP; HEMOSTASIS; HUMAN; HYPOKALEMIA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEROPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROMA; SINGLE BLIND PROCEDURE; SURGICAL MESH; SURGICAL MORTALITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; WOUND INFECTION; ADVERSE EFFECTS; AGED; BLOOD LOSS, SURGICAL; CLINICAL TRIAL; LIVER DISEASES; MIDDLE AGED; PATHOLOGY;

AGED; BLOOD LOSS, SURGICAL; COLLAGEN; FEMALE; HEMOSTASIS, SURGICAL; HEMOSTATICS; HEPATECTOMY; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84904443516     PISSN: 14352443     EISSN: 14352451     Source Type: Journal    
DOI: 10.1007/s00423-014-1203-9     Document Type: Article

References (28)

1. Nathan H, Segev DL, Mayo SC, Choti MA, Cameron AM, Wolfgang CL, Hirose K, Edil BH, Schulick RD, Pawlik TM (2012) National trends in surgical procedures for hepatocellular carcinoma: 1998-2008. Cancer 118(7):1838-1844
2. Adam R, Hoti E, Bredt LC (2010) Evolution of neoadjuvant therapy for extended hepatic metastases - have we reached our (non-resectable) limit? J Surg Oncol 102(8):922-931
3. Dimick JB, Wainess RM, Cowan JA, Upchurch GR Jr, Knol JA, Colletti LM (2004) National trends in the use and outcomes of hepatic resection. J Am Coll Surg 199(1):31-38 (Pubitemid 38813291)
4. McColl RJ, You X, Ghali WA, Kaplan G, Myers R, Dixon E (2008) Recent trends of hepatic resection in Canada: 1995-2004. J Gastrointest Surg Nov 12(11):1839-1846, discussion 1846
5. Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, Corvera C, Weber S, Blumgart LH (2002) Improvement in perioperative outcome after hepatic resection. Ann Surg 236(4):397-407
6. Asiyanbola B, Chang D, Gleisner AL, Nathan H, Choti MA, Schulick RD, Pawlik TM (2008) Operative mortality after hepatic resection: are literature-based rates broadly applicable? J Gastrointest Surg 12(5):842-851
7. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371(9617):1007-1016 (Pubitemid 351392040)
8. Ammori JB, Pelletier SJ, Lynch R, Cohn J, Ads Y, Campbell DA, Englesbe MJ (2008) Incremental costs of post-liver transplantation complications. J Am Coll Surg 206(1):89-95 (Pubitemid 350267243)
9. Brown RS Jr, Ascher NL, Lake JR, Emond JC, Bacchetti P, Randall HB, Roberts JP (1997) The impact of surgical complications after liver transplantation on resource utilization. Arch Surg 132(10):1098-1103 (Pubitemid 27433274)
10. Bechstein WO, Neuhaus P (2000) Bleeding problems in liver surgery and liver transplantation. Chirurg 71(4):363-368
11. Seyednejad H, Imani M, Jamieson T, Seifalian AM (2008) Topical haemostatic agents. Br J Surg 95(10):1197-1225
12. Jackson MR (2001) New and potential uses of fibrin sealants as an adjunct to surgical hemostasis. Am J Surg 182(2 Suppl):36S-39S
13. Kohno H, Nagasue N, Chang YC, Taniura H, Yamanoi A, Nakamura T (1992) Comparison of topical hemostatic agents in elective hepatic resection: a clinical prospective randomized trial.World J Surg 16(5):966-969, discussion 970
14. Schwartz M, Madariaga J, Hirose R, Shaver TR, Sher L, Chari R, Colonna JO 2nd, Heaton N, Mirza D, Adams R, Rees M, Lloyd D (2004) Comparison of a new fibrin sealant with standard topical hemostatic agents. Arch Surg 139(11):1148-1154 (Pubitemid 39463445)
15. Chapman WC, Clavien PA, Fung J, Khanna A, Bonham A (2000) Effective control of hepatic bleeding with a novel collagen-based composite combined with autologous plasma: results of a randomized controlled trial. Arch Surg 135(10):1200-1204, discussion 1205
16. Fischer L, Seiler CM, Broelsch CE, de Hemptinne B, Klempnauer J, Mischinger H-J, Gassel H-J, Rokkjaer M, Schauer R, Larsen PN, Tetens V, Büchler MW (2011) Hemostatic efficacy of TachoSil in liver resection compared with argon beam coagulator treatment: an open, randomized, prospective, multicenter, parallel-group trial. Surgery 149(1):48-55
17. Frilling A, Stavrou GA, Mischinger H-J, de Hemptinne B, Rokkjaer M, Klempnauer J, Thörne A, Gloor B, Beckebaum S, Ghaffar MFA, Broelsch CE (2005) Effectiveness of a new carrier-bound fibrin sealant versus argon beamer as haemostatic agent during liver resection: a randomised prospective trial. Langenbecks Arch Surg 390(2):114-120 (Pubitemid 40487434)
18. Koea JB, Batiller J, Patel B, Shen J, Hammond J, Hart J, Fischer C, Garden OJ (2013) A phase III, randomized, controlled, superiority trial evaluating the fibrin pad versus standard of care in controlling parenchymal bleeding during elective hepatic surgery. HPB (Oxford) 15(1):61-70
19. Moench C, Bechstein WO, Hermanutz V, Hoexter G, Knaebel H-P (2010) Comparison of the collagen haemostat Sangustop® versus a carrier-bound fibrin sealant during liver resection; ESSCALIVER-study. Trials 11:109
20. Takács I, Wegmann J, Horváth S, Ferencz A, Ferencz S, Jávor S, Odermatt E, Roth E, Weber G (2010) Efficacy of different hemostatic devices for severe liver bleeding: a randomized controlled animal study. Surg Innov 17(4):346-352
21. Shander A (2007) Financial and clinical outcomes associated with surgical bleeding complications. Surgery 142(4 Suppl):S20-S25
22. de Boer MT, Molenaar IQ, Porte RJ (2007) Impact of blood loss on outcome after liver resection. Dig Surg 24(4):259-264 (Pubitemid 47174041)
23. Yang T, Zhang J, Lu J-H, Yang G-S, Wu M-C, Yu W-F (2011) Risk factors influencing postoperative outcomes ofmajor hepatic resection of hepatocellular carcinoma for patients with underlying liver diseases. World J Surg 35(9):2073-2082
24. Arikawa T, Kurokawa T, Ohwa Y, Ito N, Kotake K, Nagata H, Miyachi M, Suzumura K, Nonami T (2011) Risk factors for surgical site infection after hepatectomy for hepatocellular carcinoma. Hepatogastroenterol 58(105):143-146
25. Katz SC, Shia J, Liau KH, Gonen M, Ruo L, Jarnagin WR, Fong Y, D'Angelica MI, Blumgart LH, Dematteo RP (2009) Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg 249(4):617-623
26. Gugenheim J, Bredt LC, Iannelli A (2011) A randomized controlled trial comparing fibrin glue and PlasmaJet on the raw surface of the liver after hepatic resection. Hepatogastroenterol 58(107-108):922-925
27. Garancini M, Gianotti L, Mattavelli I, Romano F, Degrate L, Caprotti R, Nespoli A, Uggeri F (2011) Bipolar vessel sealing system vs. clamp crushing technique for liver parenchyma transection. Hepatogastroenterol 58(105):127-132
28. FDA (2013) Guidance for industry. Efficacy studies to support marketing of fibrin sealant products manufactured for commercial use. http://www.fda.gov/ downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/ Guidances/Blood/ucm080795.pdf. Accessed 30 January 2013